Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 19;19(1):442–448. doi: 10.3892/ol.2019.11114

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Jia et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 1. — Effect of 5-azaC on the number of Tregs. (A) The absolute number of Tregs was significantly higher after 3 months of therapy and the difference was statistically significant [1.405±0.213 vs. 2.521±0.187 (×10⁷/l)] (mean ± SD, n=30; P=0.021). Notably, after 1 month of treatment the number of Tregs was slightly increased (left panel). In addition, the number of CD4⁺ T lymphocytes was significantly increased after 3 months (P=0.041) (right panel). (B) Representative example of an MDS patient. The number of Tregs at diagnosis was 2.416% of CD4⁺ lymphocytes. (C) After 3 months of therapy with 5-azaC, the number of Tregs was increased to 5.239% of CD4⁺ lymphocytes. 5-azaC, 5-azacytidine; Tregs, regulatory T cells; MDS, myelodysplastic syndrome.